37 results on '"Vogelzang N"'
Search Results
2. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study
3. 177Lu-PSMA-617 dans le cancer de la prostate métastatique résistant à la castration PSMA positif : analyse des traitements antérieurs et concomitants – VISION
4. Résultats de qualité de vie liée à la santé, douleur et tolérance de l’étude de phase 3 VISION du 177Lu-PSMA-617 chez des patients atteints d’un CPRCm
5. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: Final analysis of a multicentre, open-label, single-arm, phase 2 trial
6. PL02.09 Nintedanib + Pemetrexed/Cisplatin in Patients with Unresectable MPM: Phase III Results from the LUME-Meso Trial
7. P2.09-001 Effects of Tumor Burden Reduction on Survival in Epithelioid Pleural Mesothelioma
8. P1.09-011 LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-Naïve Patients with Malignant Pleural Mesothelioma
9. PS04.03 LUME-Meso Phase II/III Study: Nintedanib + Pemetrexed/Cisplatin in Chemo-Naïve Patients with Malignant Pleural Mesothelioma: Topic: Medical Oncology
10. 170TiP - LUME-Meso: Randomised phase II/III study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) followed by maintenance N or placebo (P) in chemo-naïve patients with malignant pleural mesothelioma (MPM)
11. 3LBA - Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study
12. PCN36 - Treatment Patterns And Clinical Outcomes In Pazopanib Compared With Sunitinib As First-Line Therapy For Patients With Advanced/Metastatic Renal Cell Carcinoma In A Community Oncology Setting In The United States
13. 2613 Conditional survival in de novo metastatic urothelial carcinoma: Assessment of 3,410 patients in the SEER database
14. 362 Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)
15. 840P - Outcomes of Advanced Renal Cell Carcinoma Patients (Arcc) Treated with First-Line Pazopanib (Paz) in a Us Community Oncology Setting
16. 847P - Outcomes of Advanced Renal Cell Carcinoma Patients (Arcc) Treated with Mammalian Target of Rapamycin Inhibitor (Mtori) Therapy Following First-Line Pazopanib (Paz) in a Us Community Oncology Setting
17. 808O - Inhibition of Pd-L1 By Mpdl3280A Leads to Clinical Activity in Pts with Metastatic Urothelial Bladder Cancer (Ubc)
18. 756O - Chemohormonal Therapy Versus Hormonal Therapy for Hormone Naïve High Volume Newly Metastatic Prostate Cancer (Prca): Ecog Led Phase III Randomized Trial
19. 769P - 1.5-Year Posttreatment Follow-Up of Radium-223 Dichloride (Ra-223) Safety in Patients (Pts) with Castration-Resistant Prostate Cancer (Crpc) and Symptomatic Bone Metastases from Alsympca: Characterization of Hematologic Safety Profiles
20. 870 A phase 2 trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-treated metastatic castration-resistant prostate cancer (MCRPC)
21. 244 Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC): a Phase 1 Trial in Castration-Resistant Metastatic Prostate Cancer (mCRPC)
22. LBA24 - A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone (DP) with or without Lenalidomide (LEN) in Patients with Castrate-Resistant Prostate Cancer (CRPC): The Mainsail Trial
23. 961 - Updated Analysis of a Combination Herbal Supplement Trial in Biochemically Recurrent Prostate Cancer
24. 898PD - Updated Survival, Quality of Life (QOL), and Safety Data of Radium-223 Chloride (RA-223) in Patients with Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases from the Phase 3 Double-Blind, Randomized, Multinational Study (ALSYMPCA)
25. 936P - Safety of Cytotoxic Chemotherapy Following Radium-223 Chloride (RA-223) Therapy in the Phase 3 Alsympca Study in Patients with Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases
26. 406 Phase 2 study of XL184 in a cohort of patients (pts) with castration resistant prostate cancer (CRPC) and measurable soft tissue disease
27. 7024 Phase Ib dose-finding trial of intravenous (i.v.) panobinostat (PAN) with docetaxel (DOC) and prednisone (PRED) in patients (pts) with castration resistant prostate cancer (CRPC)
28. 4504 ORAL A phase II study of continuous daily administration of sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC) – final results
29. 216 Preclinical evaluation of histone deacetylase inhibitors in malignant mesothelioma
30. P-435 Long-term survival update from the randomized phase III study of pemetrexed plus cisplatin vs cisplatin in patients with malignant pleural mesothelioma (MPM)
31. P-431 Updated multiple regression analysis of prognostic variables for survival in malignant pleural mesothelioma (MPM): Observations from a phase III study of pemetrexed plus cisplatin versus cisplatin and evolution of the regression model
32. P-407 A multicenter phase 2 trial of neo-adjuvant pemetrexed pluscisplatin followed by extrapleural pneumonectomy (EPP) and radiation (RT) for malignant pleural mesothelioma (MPM)
33. P-401 Evaluating improvement in patient-reported dyspnea and pulmonary function tests (PFTs) in patients with malignant pleural mesothelioma (MPM): An analysis as part of the 448-patient randomized pemetrexed + cisplatin versus cisplatin trial
34. 905 Documenting symptom palliation with chemotherapy using the LCSS-Meso: Results from the randomized trial of pemetrexed plus cisplatin vs cisplatin alone in patients with malignant pleural mesothelloma
35. Interleukin-2 associated linear IgA bullous dermatosis
36. 1152 Gemcitabine in the treatment of patients with advanced transitional cell carcinoma: A phase II study
37. Role of Etoposide-Based Chemotherapy in the Treatment of Patients With Refractory or Relapsing Germ Cell Tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.